SELLAS Life Sciences Plans $150 Million Public Offering of Common Stock

MT Newswires Live05:17

SELLAS Life Sciences (SLS) has commenced an underwritten public offering of $150 million of its common stock, it said Tuesday.

The late-stage clinical biopharmaceutical company said it intends to grant underwriters a 30-day option to buy up to an additional $22.5 million of shares on the same terms.

All shares in the offering will be sold by the company, it said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment